Haleon Completes US NRT Business Divestment

TL;DR

Haleon just sold its NRT business outside the US, focusing its strategy.

AI Summary

Haleon plc announced on September 30, 2024, the completion of the divestment of its Nicotine Replacement Therapy (NRT) business outside the United States. This marks a significant strategic move for the company.

Why It Matters

This divestment signals a strategic shift for Haleon, potentially allowing it to focus on core growth areas and streamline its portfolio.

Risk Assessment

Risk Level: low — The filing is an announcement of a completed business transaction and does not contain forward-looking financial projections or significant new risks.

Key Players & Entities

• Haleon plc (company) — Registrant
• Nicotine Replacement Therapy (NRT) (business) — Divested Business
• September 30, 2024 (date) — Completion Date

FAQ

Filing Documents

• a2353g.htm (6-K) — 22KB
• 0001654954-24-012460.txt ( ) — 23KB

From the Filing

OF NRT BUSINESS OUTSIDE US COMPLETE a2353g UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 30 September 2024 – “Divestment of NRT business outside US complete”   99.1   Divestment of the nicotine replacement therapy business outside of the US to Dr. Reddy's completed   30 September 2024:  Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that it has completed the divestment of its nicotine replacement therapy ("NRT") business outside of the US.   On 26 June 2024, Haleon announced that it had entered into an agreement to sell its NRT business outside of the US to Dr. Reddy's Laboratories SA ("Dr. Reddy's"), a wholly owned subsidiary of Dr. Reddy's Laboratories Limited for total consideration of up to £500m (with additional proceeds from the transfer of inventory), which comprises an upfront payment of £458m and further deferred, performance-based consideration of up to £42m payable during 2025 and H1 2026.   Amanda Mellor   Company Secretary     Enquiries   Investors Media   Sonya Ghobrial   +44 7392 784784 Zo ë  Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562       Email:  investor-relations@haleon.com   Email:  corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information please visit  www.haleon.com   SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 30, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR